Cite
HARVARD Citation
Muro, K. et al. (n.d.). P-034PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. Annals of oncology. p. . [Online].